MDMA, more commonly known as ecstasy or molly, was used in two late-stage studies by Lykos Therapeutics to determine its potential to treat PTSD. The drug is intended to be used in combination with psychological intervention, including therapy and other supportive services.
The panel of advisers will meet June 4 to deliberate on the MDMA-assisted therapy. No psychedelic-based therapy has been approved yet in the U.S., though many companies have tested such drugs for use treating a range of mental health disorders.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
